EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark ABACCEL was filed as Word mark on 03/21/2016 at the European Union Intellectual Property Office.
It was registered as a trademark on 08/29/2016.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 015246713 |
| Application date | March 21, 2016 |
| Publication date | April 8, 2016 |
| Entry date | August 29, 2016 |
| Expiration date | March 21, 2026 |
Trademark owner
Vedeckotechnicky Park Plzen, Teslova 3
30100 Plzen
CZ
30100 Plzen
CZ
Trademark representatives
Lehel Carré Gewürzmühlstrasse 11
80538 München
DE
goods and services
1
Chemicals, in particular biochemical; chemicals, in particular reagents; chemicals, in particular laboratory reagents; chemicals, in particular libraries or binding molecules; chemicals, in particular peptide or antibody libraries or peptides or antibodies; chemicals, in particular recombinant antibodies, single-stranded antibodies, diabodies, TandAbs (tandem antibodies), flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, intact immunoglobins, antibody fragments, in particular Fab or scFv fragments (antigen-binding or single chain variable fragments), or nucleic acid sequences coding for these molecules; these chemicals being used in science and industry and for research; these chemicals being used in molecular biology; these chemicals being used for identifying and characterizing molecules, in particular proteins or nucleic acids; these chemicals being used for identifying and characterizing enzymes or signal transduction molecules
5
Pharmaceutical and veterinary preparations in form of binding molecules, in particular peptides or antibodies, in particular recombinant antibodies, single-stranded antibodies, diabodies, TandAbs (tandem antibodies), flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, intact immunoglobins, antibody fragments, in particular Fab or scFv fragments (antigen-binding or single chain variable fragments), or nucleic acid sequences coding for these molecules; pharmaceutical and veterinary preparations in form of binding molecules or nucleic acid sequences coding for these molecules for the treatment or diagnosing of infectious or inflammatory illnesses and tumors
42
Scientific and technological services and research projects, in particular for the preparation of peptide or antibody libraries, or for the identification and characterisation of binding molecules; scientific and technological services and research projects, in particular for the preparation, identification and/or characterisation of peptides or antibodies; scientific and technological services and research projects, in particular for the preparation, identification and/or characterisation of recombinant antibodies, single-chain antibodies, diabodies, TandAbs (tandem antibodies), flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, or antibody fragments, in particular Fab or scFv fragments (antigen-binding or single chain variable fragments), or of nucleic acid sequences coding for these molecules; scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries; scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries; scientific and technological services and research projects in relation to antibody development strategies; scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates; scientific and technological services and research projects in relation to multi-factor antibody optimization; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and/or human properties; scientific and technological services and research projects in relation to human and non-human lead antibody technology
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| February 21, 2022 | Change Representative, Published | ||
| January 16, 2019 | Change Representative, Published | ||
| January 16, 2019 | Change Representative, Published | ||
| April 8, 2016 | Transfer / Change of address, Published |
ID: 11015246713